drugset
drugset / Trial / NCT05465174

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174 ↗

Phase 2 Recruiting 57 enrolled Sabine Mueller, MD, PhD Day One Biopharmaceuticals, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Timeline

Start
2022-09-12
Primary completion
2027-03-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tovorafenib Small molecule — Oral

Indications

craniopharyngioma